Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Carboplatin/Paclitaxel +/- Targeted Agents in Breast Cancer
NCT02436993Phase 2Active, not recruiting
- Sponsor
- University of California, Irvine
- Start
- Apr 2015
- Primary completion
- Nov 2023
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin, Paclitaxel Micelles for Injection, bevacizumab, trastuzumab, pertuzumab in breast cancer, sponsored by University of California, Irvine. Started Apr 2015; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02436993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02436993.